Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus

BACKGROUND: It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease. METHODS AND RESULTS: We administered 100 mg of cana...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Diabetol Metab Syndr
Autors principals: Yagi, Shusuke, Hirata, Yukina, Ise, Takayuki, Kusunose, Kenya, Yamada, Hirotsugu, Fukuda, Daiju, Salim, Hotimah Masdan, Maimaituxun, Gulinu, Nishio, Susumu, Takagawa, Yuriko, Hama, Saori, Matsuura, Tomomi, Yamaguchi, Koji, Tobiume, Takeshi, Soeki, Takeshi, Wakatsuki, Tetsuzo, Aihara, Ken-ichi, Akaike, Masashi, Shimabukuro, Michio, Sata, Masataka
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2017
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5628447/
https://ncbi.nlm.nih.gov/pubmed/29034006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13098-017-0275-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars